Syndax Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the …

Biotechnology
US, Waltham [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of SNDX's Analysis
CIK: 1395937 CUSIP: 87164F105 ISIN: US87164F1057 LEI: - UEI: -
Secondary Listings
SNDX has no secondary listings inside our databases.